|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder | |||||||||||
| 化学式 | C24H24N2O3S |
||||||||||||||
| 分子量 | 420.52 | CAS No. | 222716-34-9 | ||||||||||||
| Solubility (25°C)* | 体外 | DMSO | 5 mg/mL (11.89 mM) | ||||||||||||
| Water | Insoluble | ||||||||||||||
| Ethanol | Insoluble | ||||||||||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||||||||||
| 製品説明 | SZL P1-41 (compound #25) is a specific inhibitor of S-phase kinase-associated protein 2 (Skp2) that indeed binds to Skp2, prevents Skp2-Skp1 interaction and inhibits Skp2 SCF E3 ligase activity, which consequently suppresses survival of cancer cells and cancer stem cells. SZL P1-41 causes higher apoptosis rates in cancer cells. |
|---|---|
| in vitro | SZL P1-41 indeed binds to Skp2, prevents Skp2-Skp1 interaction and inhibits this compound's SCF E3 ligase activity, which consequently suppresses survival of cancer cells and cancer stem cells.[1] |
| in vivo | SZL P1-41 also exhibits potent anti-tumor activity in animal studies.[1] |
| 細胞アッセイ | 細胞株 | PC3 cells |
|---|---|---|
| 濃度 | 10 μM, 20 μM | |
| 反応時間 | 4 days | |
| 実験の流れ | For Skp2 inhibitor administration, 5~10 × 103 of cells are seeded in 12 wells in triplicate for 24 h and then treated with various doses of SZL P1-41 (refreshed every two days). After four days, cells are harvested, stained with 0.4% blue solution, and viable cells are counted using hemocytometer under microscope by blue dye exclusion method. For treatment, 8× 103 of PC3 cells with were seeded in 12 wells in triplicate for 24 h and then treated with various doses of this compound for four and three days, respectively (refreshed every two days). |
|
| 動物実験 | 動物モデル | nude mice bearing A549 xenograft tumors, nude mice bearing PC3 xenograft tumors |
| 投薬量 | 80 mg/kg, 40 mg/kg | |
| 投与方法 | IP |
|
| LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer [ J Immunother Cancer, 2024, 12(12)e009444] | PubMed: 39694700 |
| Gastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis [ Cell Death Discov, 2023, 9(1):364] | PubMed: 37779163 |
| Gastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis [ Cell Death Discov, 2023, 9(1):364] | PubMed: 37779163 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。